TrialNet: Diabetes Type 1 Prevention
TrialNet:1 型糖尿病预防
基本信息
- 批准号:9066681
- 负责人:
- 金额:$ 58.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-30 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:Ancillary StudyAutoimmune DiseasesAutoimmune ProcessB-LymphocytesBiological MarkersBlood GlucoseC-PeptideClinicalClinical ResearchConduct Clinical TrialsDevelopmentDiabetes MellitusDietary InterventionDiseaseDisease ProgressionEnrollmentFunctional disorderFutureGoalsHealthHealthcare SystemsHumanImmuneImmune ToleranceImmunologicsImmunotherapyInsulin-Dependent Diabetes MellitusInterventionKnowledgeMetabolicParticipantPathogenesisPhysiciansPopulations at RiskPreventionProductivityProtocols documentationRecruitment ActivityScientistStudy SubjectT-LymphocyteUnited StatesWorkcosthuman subjectimpaired glucose toleranceimprovedmonocytenext generationprevent
项目摘要
DESCRIPTION (provided by applicant): Multiple treatments that can change the course of type 1 diabetes have been identified over the last several years through the efforts of TrialNet, the Immune Tolerance Network and others. Although these immune therapies can stop disease progression in those with elevated blood sugars, the effect has proven to be transient in most study subjects. The ongoing effort of Type 1 Diabetes TrialNet, its Clinical Centers and affiliates
is to continue to develop better therapies to prevent and reverse type 1 diabetes in human subjects. The Barbara Davis Center and its affiliate network has been a central contributor to these efforts from the beginning of DPT-1 through TrialNet and we hope with renewal of our Clinical Center to be able to continue to push towards these aims as well as develop the next generation of physician-scientists who can build on the work accomplished so far. Our aim is not only to conduct excellent clinical research which can answer the main study questions being examined: most often metabolic - development of impaired glucose tolerance, overt diabetes or reduced C-peptide, but also to develop immune biomarkers which can help us better understand the pathogenesis of disease progression and identify secondary markers of responder groups that allow us to better tailor our therapies to achieve successful prevention of T1D.
描述(由申请人提供):在过去几年中,通过TrialNet、免疫耐受网络等的努力,已经确定了多种可以改变1型糖尿病病程的治疗方法。虽然这些免疫疗法可以阻止血糖升高患者的疾病进展,但在大多数研究对象中,这种效果被证明是短暂的。1型糖尿病试验网、其临床中心和附属机构正在努力
是继续开发更好的治疗方法来预防和逆转人类受试者的1型糖尿病。芭芭拉·戴维斯中心及其附属网络一直是这些努力的核心贡献者,从DPT-1开始到TrialNet,我们希望随着我们临床中心的更新,能够继续推动这些目标,并培养下一代的医生科学家,他们可以在迄今为止完成的工作的基础上再接再厉。我们的目标不仅是进行优秀的临床研究,可以回答正在研究的主要研究问题:最常见的是代谢-葡萄糖耐量受损,明显的糖尿病或C肽减少,还可以开发免疫生物标志物,帮助我们更好地了解疾病进展的发病机制,并确定反应组的次要标志物,使我们能够更好地定制我们的治疗,以实现成功的治疗。预防T1 D
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER A GOTTLIEB其他文献
PETER A GOTTLIEB的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER A GOTTLIEB', 18)}}的其他基金
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES
新发 1 型糖尿病的免疫治疗试验
- 批准号:
7719503 - 财政年份:2008
- 资助金额:
$ 58.72万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 58.72万 - 项目类别:
Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
- 批准号:
23H02155 - 财政年份:2023
- 资助金额:
$ 58.72万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
- 批准号:
10788032 - 财政年份:2023
- 资助金额:
$ 58.72万 - 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
- 批准号:
23K14742 - 财政年份:2023
- 资助金额:
$ 58.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
- 批准号:
10864719 - 财政年份:2023
- 资助金额:
$ 58.72万 - 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
- 批准号:
10586562 - 财政年份:2023
- 资助金额:
$ 58.72万 - 项目类别:
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
- 批准号:
10593224 - 财政年份:2023
- 资助金额:
$ 58.72万 - 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
- 批准号:
23K06589 - 财政年份:2023
- 资助金额:
$ 58.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
- 批准号:
10623380 - 财政年份:2023
- 资助金额:
$ 58.72万 - 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
- 批准号:
10735148 - 财政年份:2023
- 资助金额:
$ 58.72万 - 项目类别: